A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
prohibit the approval of new abortion drugs, to prohibit 
investigational use exemptions for abortion drugs, and 
02:46 Feb 18, 2021
H554
2 
•HR 554 IH
to impose additional regulatory requirements with respect 
to previously approved abortion drugs, and for other 
purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Support And Value 
4
Expectant Moms and Babies Act of 2021’’ or the ‘‘SAVE 
5
Moms and Babies Act of 2021’’. 
6
SEC. 2. ABORTION DRUGS PROHIBITED. 
7
(a) IN GENERAL.—Section 505 of the Federal Food, 
8
Drug, and Cosmetic Act (21 U.S.C. 355) is amended by 
9
adding at the end the following: 
10
‘‘(z) ABORTION DRUGS.— 
11
‘‘(1) PROHIBITIONS.—The Secretary shall not 
12
approve— 
13
‘‘(A) any application submitted under sub-
14
section (b) or (j) for marketing an abortion 
15
drug; or 
16
‘‘(B) grant an investigational use exemp-
17
tion under subsection (i) for— 
18
‘‘(i) an abortion drug; or 
19
‘‘(ii) any investigation in which the 
20
human embryo or human fetus of a woman 
21
known to be pregnant is knowingly de-
22
stroyed. 
23
02:46 Feb 18, 2021
H554
3 
•HR 554 IH
‘‘(2) 
PREVIOUSLY
APPROVED
ABORTION 
1
DRUGS.—If an approval described in paragraph (1) 
2
is in effect for an abortion drug as of the date of 
3
enactment of the Support And Value Expectant 
4
Moms and Babies Act of 2021, the Secretary shall— 
5
‘‘(A) not approve any labeling change— 
6
‘‘(i) to approve the use of such abor-
7
tion drug after 70 days gestation; or 
8
‘‘(ii) to approve the dispensing of such 
9
abortion drug by any means other than in- 
10
person administration by the prescribing 
11
health care practitioner; 
12
‘‘(B) treat such abortion drug as subject to 
13
section 503(b)(1); and 
14
‘‘(C) require such abortion drug to be sub-
15
ject to a risk evaluation and mitigation strategy 
16
under section 505–1 that at a minimum— 
17
‘‘(i) requires health care practitioners 
18
who prescribe such abortion drug— 
19
‘‘(I) to be certified in accordance 
20
with the strategy; and 
21
‘‘(II) to not be acting in their ca-
22
pacity as a pharmacist; 
23
02:46 Feb 18, 2021
H554
4 
•HR 554 IH
‘‘(ii) as part of the certification proc-
1
ess referred to in clause (i), requires such 
2
practitioners— 
3
‘‘(I) to have the ability to assess 
4
the duration of pregnancy accurately; 
5
‘‘(II) to have the ability to diag-
6
nose ectopic pregnancies; 
7
‘‘(III) to have the ability to pro-
8
vide surgical intervention in cases of 
9
incomplete abortion or severe bleed-
10
ing; 
11
‘‘(IV) to have the ability to en-
12
sure patient access to medical facili-
13
ties equipped to provide blood trans-
14
fusions and resuscitation, if necessary; 
15
and 
16
‘‘(V) to report any deaths or 
17
other adverse events associated with 
18
the use of such abortion drug to the 
19
Food and Drug Administration and to 
20
the manufacturer of such abortion 
21
drug, identifying the patient by a non- 
22
identifiable reference and the serial 
23
number from each package of such 
24
abortion drug; 
25
02:46 Feb 18, 2021
H554
5 
•HR 554 IH
‘‘(iii) limits the dispensing of such 
1
abortion drug to patients— 
2
‘‘(I) in a clinic, medical office, or 
3
hospital by means of in-person admin-
4
istration by the prescribing health 
5
care practitioner; and 
6
‘‘(II) not in pharmacies or any 
7
setting other than the health care set-
8
tings described in subclause (I); 
9
‘‘(iv) requires the prescribing health 
10
care practitioner to give to the patient doc-
11
umentation on any risk of serious com-
12
plications associated with use of such abor-
13
tion drug and receive acknowledgment of 
14
such receipt from the patient; 
15
‘‘(v) requires all known adverse events 
16
associated with such abortion drug to be 
17
reported, excluding any individually identi-
18
fiable patient information, to the Food and 
19
Drug Administration by the— 
20
‘‘(I) manufacturers of such abor-
21
tion drug; and 
22
‘‘(II) prescribers of such abortion 
23
drug; and 
24
02:46 Feb 18, 2021
H554
6 
•HR 554 IH
‘‘(vi) requires reporting of administra-
1
tion of the abortion drug as required by 
2
State law, or in the absence of a State law 
3
regarding such reporting, in the same 
4
manner as a surgical abortion. 
5
‘‘(3) REPORTING
ON
ADVERSE
EVENTS
BY 
6
OTHER
HEALTH
CARE
PRACTITIONERS.—The Sec-
7
retary shall require all other health care practi-
8
tioners to report to the Food and Drug Administra-
9
tion any adverse events experienced by their patients 
10
that are connected to use of an abortion drug, ex-
11
cluding any individually identifiable patient informa-
12
tion. 
13
‘‘(4) RULE
OF
CONSTRUCTION.—Nothing in 
14
this section shall be construed to restrict the author-
15
ity of the Secretary, or of a State, to establish, im-
16
plement, and enforce requirements and restrictions 
17
with respect to abortion drugs under provisions of 
18
law other than this section that are in addition to 
19
the requirements and restrictions under this section. 
20
‘‘(5) DEFINITIONS.—In this section: 
21
‘‘(A) The term ‘abortion drug’ means any 
22
drug, substance, or combination of drugs or 
23
substances that is intended for use or that is in 
24
02:46 Feb 18, 2021
H554
7 
•HR 554 IH
fact used (irrespective of how the product is la-
1
beled)— 
2
‘‘(i) to intentionally kill the unborn 
3
child of a woman known to be pregnant; or 
4
‘‘(ii) to intentionally terminate the 
5
pregnancy of a woman known to be preg-
6
nant, with an intention other than— 
7
‘‘(I) to produce a live birth; or 
8
‘‘(II) to remove a dead unborn 
9
child. 
10
‘‘(B) The term ‘adverse event’ includes 
11
each of the following: 
12
‘‘(i) A fatality. 
13
‘‘(ii) An ectopic pregnancy. 
14
‘‘(iii) A hospitalization. 
15
‘‘(iv) A blood loss requiring a trans-
16
fusion. 
17
‘‘(v) An infection, including endo-
18
metritis, pelvic inflammatory disease, and 
19
pelvic infections with sepsis. 
20
‘‘(vi) A severe infection. 
21
‘‘(C) The term ‘gestation’ means the pe-
22
riod of days beginning on the first day of the 
23
last menstrual period. 
24
02:46 Feb 18, 2021
H554
8 
•HR 554 IH
‘‘(D) The term ‘health care practitioner’ 
1
means any individual who is licensed, reg-
2
istered, or otherwise permitted, by the United 
3
States or the jurisdiction in which the indi-
4
vidual practices, to prescribe drugs subject to 
5
section 503(b)(1). 
6
‘‘(E) The term ‘unborn child’ means an in-
7
dividual organism of the species homo sapiens, 
8
beginning at fertilization, until the point of 
9
being born alive as defined in section 8(b) of 
10
title 1, United States Code.’’. 
11
(b) ONGOING INVESTIGATIONAL USE.—In the case of 
12
any investigational use of a drug pursuant to an investiga-
13
tional use exemption under section 505(i) of the Federal 
14
Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) that 
15
was granted before the date of enactment of this Act, such 
16
exemption is deemed to be rescinded as of the day that 
17
is 3 years after the date of enactment of this Act if the 
18
Secretary would be prohibited by section 505(z)(1)(B) of 
19
the Federal Food, Drug, and Cosmetic Act, as added by 
20
subsection (a), from granting such exemption as of such 
21
day. 
22
Æ 
02:46 Feb 18, 2021
H554
